You are here:

tiotropium (Spiriva Respimat)

Advice

following an abbreviated resubmission:

tiotropium (Spiriva Respimat®) is accepted for use within NHS Scotland.

Indication under review: as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).

Tiotropium (Spiriva Respimat®) was previously accepted for restricted use in patients who have poor manual dexterity and therefore have difficulty using the HandiHaler device. Since tiotropium (Spiriva) Respimat is now available at no additional cost compared with tiotropium (Spiriva) HandiHaler the restriction has been removed.

Drug Details

Drug Name: tiotropium (Spiriva Respimat)
SMC Drug ID: 411/07
Manufacturer: Boehringer Ingelheim Ltd
Indication: As a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).
BNF Category:
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 11 December 2017

Archived Advice

Abbreviated Submission 12 November 2007

Back